unoprostone isopropyl

Ligand id: 8282

Name: unoprostone isopropyl

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: unoprostone isopropyl

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 17
Topological polar surface area 83.83
Molecular weight 424.32
XLogP 5.39
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

References
1. Bazan NG. (2006)
The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling.
Cell. Mol. Neurobiol.26 (4-6): 901-13. [PMID:16897369]
2. Cuppoletti J, Malinowska DH, Tewari KP, Chakrabarti J, Ueno R. (2007)
Cellular and molecular effects of unoprostone as a BK channel activator.
Biochim. Biophys. Acta1768 (5): 1083-92. [PMID:17307133]
3. Harms NV, Toris CB. (2013)
Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease.
Expert Opin Pharmacother14 (1): 105-13. [PMID:23199345]
4. Sharif NA, Kelly CR, Crider JY. (2003)
Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.
Invest. Ophthalmol. Vis. Sci.44 (2): 715-21. [PMID:12556403]
5. Tawada A, Sugawara T, Ogata K, Hagiwara A, Yamamoto S. (2013)
Improvement of central retinal sensitivity six months after topical isopropyl unoprostone in patients with retinitis pigmentosa.
Indian J Ophthalmol61 (3): 95-9. [PMID:23514642]
6. Tsuruma K, Tanaka Y, Shimazawa M, Mashima Y, Hara H. (2011)
Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction, by activating BK channels.
Mol. Vis.17: 3556-65. [PMID:22219651]
7. Yamamoto S, Sugawara T, Murakami A, Nakazawa M, Nao-I N, Machida S, Wada Y, Mashima Y, Myake Y. (2012)
Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study.
Ophthalmol Ther1 (1): 5. [PMID:25135585]